Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study

X
Trial Profile

An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab; Sunitinib; Vinflunine
  • Indications Bladder cancer; Non-small cell lung cancer; Renal cancer; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms IMbrella A
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 17 Feb 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
    • 13 Jan 2024 This trial has been completed in Czech Republic.
    • 15 Nov 2023 Number of treatment arms increased from 1 to 3 by the addition of an experimental arm (Combined Agents with Atezolizumab) and an active comparator (Bevacizumab) arm. Study design is changed from single-group assignment to parallel.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top